TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24335790

Group type: EXPERIMENTAL
Intervention: Clinical benchmarking tool (Essence of Care)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Detailed information about residents and continence services contact details
Number of subjects: 6
Study: 20080918

Group type: EXPERIMENTAL
Intervention: IA injection of 40 mg triamcinolone acetonide
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1 cc 0.9% saline (placebo)
Number of subjects: 79
Study: 19003741

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cell treatment (injected at 40 sites into the ischemic limb)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (sham bone marrow punction and 40 saline injections)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cell treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15668596

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12897302

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) 100 microg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10447988

Group type: COMPARATOR
Intervention: Conceptual number mismatch (grammatical number singular, conceptual number plural)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sentence/picture matching test
Number of subjects: 0
Study: 8526834

Group type: EXPERIMENTAL
Intervention: Cold body-cold arm (CB-CA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Warm body-cold arm (WB-CA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cold body-warm arm (CB-WA)
Number of subjects: 6
Study: 1971767

Group type: EXPERIMENTAL
Intervention: Slow withdrawal (SW)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Abrupt withdrawal under propranolol cover (PW)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (SW and PW)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Younger subjects and those more severely anxious at the start
Number of subjects: 31
Study: 85052

Group type: EXPERIMENTAL
Intervention: P.U.V.A. (8‐methoxypsoralen and long‐wave ultraviolet light)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Dithranol
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: P.U.V.A.
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: P.U.V.A. for patients who failed dithranol or needed methotrexate
Number of subjects: 224

Group type: COMPARATOR
Intervention: Dithranol for patients who failed P.U.V.A.
Number of subjects: 224
Study: 30924301

Group type: COMPARATOR
Intervention: Subcision and needling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcision, needling, and topical application of PRP
Number of subjects: 30
Study: 28318619

Group type: EXPERIMENTAL
Intervention: Obesity motivational intervention group with previously trained nurse (G1)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lower intensity consultation, non-motivational group, with digital platform support (G2)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Recommendation to lose weight and usual follow-up (G3)
Number of subjects: 176

Group type: COMPARATOR
Intervention: G1 vs G3 for TG
Number of subjects: 176

Group type: COMPARATOR
Intervention: G1 vs G2 for HDL-C
Number of subjects: 176
Study: 25819042

Group type: EXPERIMENTAL
Intervention: Inosine pranobex (1 g four times daily)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Acyclovir (200 mg five times daily)
Number of subjects: 288
Study: 24321275

Group type: EXPERIMENTAL
Intervention: C7-T8 relative phase at 0.67 and 0.89 m/s
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: C7-sacrum and T8-sacrum relative phases
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: C7-T8 and T8-sacrum relative phases
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: T8-sacrum relative phase
Number of subjects: 38
Study: 21594560

Group type: EXPERIMENTAL
Intervention: D-cycloserine (100 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Valproic acid (400 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of D-cycloserine and Valproic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19273715

Group type: EXPERIMENTAL
Intervention: Point of Information and Support (PIS)
Number of subjects: 3286

Group type: COMPARATOR
Intervention: No PIS (Control)
Number of subjects: 3286
Study: 17211242

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 46
Study: 15564035

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation during sleep
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference group (no non-invasive ventilation)
Number of subjects: 12
Study: 11535952

Group type: EXPERIMENTAL
Intervention: Cefaclor (375 mg BID for 10 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (625 mg BID for 10 days)
Number of subjects: 200
Study: 9692813

Group type: EXPERIMENTAL
Intervention: 10 microg/kg G‐CSF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 24 microg/kg G‐CSF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G‐CSF treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G‐CSF mobilization
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 6 or more cycles of melphalan pretreatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 24
Study: 8778145

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1000 mg daily for 4 weeks
Number of subjects: 10
Study: 1969197

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7276678

Group type: EXPERIMENTAL
Intervention: Group A: MFC (mitomycin C, 5 fluorouracil, cytosine arabinoside) intravenously for 5 weeks, followed by oral 5 FU dry syrup for 2 years
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Group B: FT 207 substituted for 5 FU, same schedule as Group A
Number of subjects: 244

Group type: COMPARATOR
Intervention: Group C: no chemotherapy added to surgery
Number of subjects: 244
Study: 31563527

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2311

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2311
Study: 29752225

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Childbirth and Parenting programme
Number of subjects: 104

Group type: COMPARATOR
Intervention: Traditional education classes
Number of subjects: 104
Study: 27888052

Group type: EXPERIMENTAL
Intervention: NSAIDs (used in 2368 patients, 40.2%)
Number of subjects: 5887

Group type: COMPARATOR
Intervention: No NSAIDs (not using NSAIDs)
Number of subjects: 5887
Study: 25685056

Group type: EXPERIMENTAL
Intervention: Suggestion
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Dreamfilm
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (etomidate & sevoflurane)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (propofol & sevoflurane)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (propofol & propofol)
Number of subjects: 270
Study: 24164569

Group type: EXPERIMENTAL
Intervention: SRP + probiotic (Lactobacillus reuteri lozenges, used two times a day for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 30
Study: 20146674

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day (n=19)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day (n=19)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No statin (control group, n=15)
Number of subjects: 53
Study: 18985817

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Bifidobacterium lactis DN-173010
Number of subjects: 135
Study: 16889324

Group type: EXPERIMENTAL
Intervention: Individual art therapy for 1 hour/week during postoperative radiotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study: 12911442

Group type: EXPERIMENTAL
Intervention: Multimodal smoking cessation intervention (individual counseling + optional nicotine replacement therapy)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Usual care (standard counseling from a midwife)
Number of subjects: 647
Study: 11004357

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (500-microg tablet vaginally, every 6 hours for maximum of two doses)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prostaglandin E2 (3-mg tablet vaginally, every 6 hours for maximum of two doses)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate and Prostaglandin E2
Number of subjects: 110
Study: 8951258

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Computer simulated driving test (ADHD group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (without ADHD)
Number of subjects: 48
Study: 1903167

Group type: COMPARATOR
Intervention: Urokinase (UK) 96 x 10(4)IU
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: rt-PA2 (2000 x 10(4)IU, 33 mg)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: rt-PA3 (3000 x 10(4)IU, 50 mg)
Number of subjects: 198
Study: 6938996

Group type: EXPERIMENTAL
Intervention: Haloperidol plus lithium
Number of subjects: 36

Group type: COMPARATOR
Intervention: Haloperidol plus placebo
Number of subjects: 36
Study: 31685315

Group type: EXPERIMENTAL
Intervention: Thermophilic anaerobic digestion (55 ℃)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mesophilic anaerobic digestion (35 ℃)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both temperatures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermophilic and mesophilic AD
Number of subjects: 0
Study: 31519221

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 28257741

Group type: EXPERIMENTAL
Intervention: Surgery-first approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orthodontics-first approach
Number of subjects: 50
Study: 26352164

Group type: EXPERIMENTAL
Intervention: Novel community health worker‐based multilevel discharge intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard discharge care (usual care)
Number of subjects: 300
Study: 23399456

Group type: EXPERIMENTAL
Intervention: Surface peroneal nerve stimulator (PNS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (ankle-foot orthosis or no device)
Number of subjects: 110
Study: 22025372

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 8012

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 8012
Study: 19882056

Group type: EXPERIMENTAL
Intervention: 400 mg oral palm vitamin E
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1.5 g oral glucosamine sulphate
Number of subjects: 79
Study: 17492948

Group type: EXPERIMENTAL
Intervention: 1 mg of 17beta‐oestradiol orally combined with 100 mg progesterone
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 50 microg of 17beta‐oestradiol transdermally combined with 100 mg progesterone
Number of subjects: 196

Group type: COMPARATOR
Intervention: Triple dummy placebo
Number of subjects: 196
Study: 15190690

Group type: EXPERIMENTAL
Intervention: Flexible-head toothbrush 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flexible-head toothbrush 2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-flexible-head toothbrush (control)
Number of subjects: 20
Study: 11499745

Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium restriction (sodium intake <100 mmol/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Aerobic exercise (daily walking)
Number of subjects: 35
Study: 9923414

Group type: EXPERIMENTAL
Intervention: Tacrolimus (target concentration range 10-30 ng/mL during the first 8 weeks, tapering 20% per month during months 3-6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (target concentration range 150-450 ng/mL during the first 8 weeks, tapering 20% per month during months 3-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine (both treatments)
Number of subjects: 0
Study: 8117018

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 107

Group type: COMPARATOR
Intervention: No drain (control)
Number of subjects: 107
Study: 3405718

Group type: EXPERIMENTAL
Intervention: Social skills program (experimental group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 16
Study: 29504468

Group type: EXPERIMENTAL
Intervention: Face-to-face delivery of the PILI@Work Program
Number of subjects: 217

Group type: COMPARATOR
Intervention: DVD delivery of the PILI@Work Program
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Both interventions (face-to-face and DVD)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Attendance in Phase 1 of the intervention
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure
Number of subjects: 217
Study: 27147120

Group type: EXPERIMENTAL
Intervention: 50,000 IU oral vitamin D weekly for eight weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo weekly for eight weeks
Number of subjects: 60
Study: 25709408

Group type: EXPERIMENTAL
Intervention: Iontophoretic application of 1% diclofenac (DF) for 20 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Occlusive application of 1% diclofenac (DF) for 20 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Passive application of 1% diclofenac (DF) for 20 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no application)
Number of subjects: 60
Study: 23510162

Group type: EXPERIMENTAL
Intervention: Visual feedback and multimodal games
Number of subjects: 48
Study: 21395878

Group type: EXPERIMENTAL
Intervention: ST11-fermented milk
Number of subjects: 31
Study: 19093003

Group type: EXPERIMENTAL
Intervention: Rotating walker
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard point-light walkers (non-rotating)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Rotating cuboid (non-biological object)
Number of subjects: 4
Study: 16574032

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 994

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 994
Study: 14570299

Group type: EXPERIMENTAL
Intervention: Linear transformation (u = 0.44v + 0.49)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Curvilinear transformation (u = 1 - [1 - v]1.6)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Alternative linear model (u = v + 0.018)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Alternative published curvilinear model (u = 1 - [1 - v]2.3)
Number of subjects: 299
Study: 10876454

Group type: EXPERIMENTAL
Intervention: Cephalad group (needle orifice direction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caudad group (needle orifice direction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalad group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caudad group
Number of subjects: 0
Study: 9206757

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEP) recorded before and after cervical spine surgery
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: P14 and P30 potentials
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SEP recording
Number of subjects: 11
Study: 8471899

Group type: EXPERIMENTAL
Intervention: 3-day norfloxacin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-day norfloxacin treatment
Number of subjects: 0
Study: 2951925

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 30
Study: 31368271

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX-UE10) combined with Wang's Baochi Pills
Number of subjects: 201

Group type: COMPARATOR
Intervention: Wang's Baochi Pills only (Control)
Number of subjects: 201
Study: 29909301

Group type: EXPERIMENTAL
Intervention: Transdiagnostic CBT
Number of subjects: 19
Study: 27551820

Group type: EXPERIMENTAL
Intervention: Self-controlled group (chose difficulty progression)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-controlled group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Yoked group (no choice in difficulty progression)
Number of subjects: 60
Study: 24812628

Group type: EXPERIMENTAL
Intervention: High-intensity swim training (HIT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moderate-intensity swim training (MOD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 62
Study: 22217551

Group type: EXPERIMENTAL
Intervention: Autofluorescence visualization device (VELscope) in addition to white light examination
Number of subjects: 289

Group type: COMPARATOR
Intervention: Conventional examination with white light
Number of subjects: 289
Study: 20060162

Group type: EXPERIMENTAL
Intervention: 800 mcg sublingual misoprostol
Number of subjects: 809

Group type: COMPARATOR
Intervention: 40 IU intravenous oxytocin
Number of subjects: 809
Study: 17585405

Group type: EXPERIMENTAL
Intervention: Community-based nurse and pharmacist active screening team
Number of subjects: 0
Study: 16297553

Group type: EXPERIMENTAL
Intervention: Trapezius myalgia (TM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (TM and CON)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 19
Study: 12066254

Group type: EXPERIMENTAL
Intervention: Mild hypertension (H)
Number of subjects: 29

Group type: COMPARATOR
Intervention: White-coat hypertension (WH)
Number of subjects: 29
Study: 9485240

Group type: EXPERIMENTAL
Intervention: Lower anticoagulation protocol (activated clotting time, > 250 seconds)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Full anticoagulation protocol (activated clotting time, > 450 seconds)
Number of subjects: 244
Study: 8749950

Group type: EXPERIMENTAL
Intervention: CISCA chemotherapy with rhG-CSF (lenograstim) at 2 mg/kg/day subcutaneously on days 3 to 16 (until day 14 for the 14-day interval group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CISCA chemotherapy with rhG-CSF
Number of subjects: 16
Study: 2611119

Group type: EXPERIMENTAL
Intervention: H2 A + RF alginate antacid (Riflux Forte)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: H2 A + S non‐alginate antacid (Siloxogene)
Number of subjects: 2
Study: 30922261

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Re-trans-catheter arterial chemoembolization (re-TACE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 120
Study: 28375205

Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25740264

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (10 g orally once a day for 3 weeks after initial testing)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study: 24579364

Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitive moxibustion
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Medication (Sanqi Tongshu capsules)
Number of subjects: 144
Study: 20466870

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg once daily for days 1-7, 0.5 mg twice daily for days 8-14, 1 mg twice daily for days 15-21)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg once daily for days 1-14, 0.5 mg twice daily for days 15-21)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg once daily for days 1-14, 1 mg once daily for days 15-21)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18627375

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg kg(‐1)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg(‐1)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study: 16618781

Group type: EXPERIMENTAL
Intervention: Polymorphisms in IL-1B, IL-6, IL-8, and IL-10
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Haplotypes of IL-10 SNPs
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Use of nonsteroidal anti-inflammatory drugs
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Early or advanced prostate cancers
Number of subjects: 1320
Study: 12456509

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy followed by myeloablative therapy (cyclophosphamide, total body irradiation, and autologous stem cell reinfusion)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Intensified chemotherapy alone (intermediate-dose melphalan [IDM] without stem cell rescue)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy followed by myeloablative therapy
Number of subjects: 261

Group type: COMPARATOR
Intervention: Intensified chemotherapy alone
Number of subjects: 261
Study: 11197214

Group type: EXPERIMENTAL
Intervention: Am80 therapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Am80 therapy with subsequent HLA-matched allogeneic bone marrow transplantation (BMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Am80 therapy without BMT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PML-RAR alpha fusion transcript undetectable
Number of subjects: 24
Study: 8899270

Group type: EXPERIMENTAL
Intervention: Oral tetrathiomolybdate (TM) followed by oral zinc (Zn) maintenance therapy
Number of subjects: 14
Study: 1379107

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Finasteride 10 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 6148164

Group type: EXPERIMENTAL
Intervention: Somatostatin (3 micrograms/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 30660644

Group type: EXPERIMENTAL
Intervention: Allergen exposure
Number of subjects: 12